TWI698258B - 醫藥組合物 - Google Patents
醫藥組合物 Download PDFInfo
- Publication number
- TWI698258B TWI698258B TW108112937A TW108112937A TWI698258B TW I698258 B TWI698258 B TW I698258B TW 108112937 A TW108112937 A TW 108112937A TW 108112937 A TW108112937 A TW 108112937A TW I698258 B TWI698258 B TW I698258B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- present
- composition
- salt
- aluminum phosphate
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 91
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract description 33
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 27
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 27
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 27
- QQZIUHOKWDFXEY-UHFFFAOYSA-N tribromo(nitro)methane Chemical compound [O-][N+](=O)C(Br)(Br)Br QQZIUHOKWDFXEY-UHFFFAOYSA-N 0.000 claims abstract description 23
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 55
- 239000000499 gel Substances 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 24
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 24
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 24
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 20
- 239000000796 flavoring agent Substances 0.000 claims description 20
- -1 polydimethylsiloxane Polymers 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 12
- 230000002496 gastric effect Effects 0.000 claims description 11
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 239000004376 Sucralose Substances 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 235000019408 sucralose Nutrition 0.000 claims description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 230000008673 vomiting Effects 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- 201000006549 dyspepsia Diseases 0.000 claims description 7
- 229920001817 Agar Polymers 0.000 claims description 6
- 229940008099 dimethicone Drugs 0.000 claims description 6
- 239000001814 pectin Substances 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 206010000060 Abdominal distension Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 208000024330 bloating Diseases 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 4
- 206010020601 Hyperchlorhydria Diseases 0.000 claims description 4
- 206010020710 Hyperphagia Diseases 0.000 claims description 4
- 206010028813 Nausea Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 230000004596 appetite loss Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 208000024798 heartburn Diseases 0.000 claims description 4
- 208000019017 loss of appetite Diseases 0.000 claims description 4
- 235000021266 loss of appetite Nutrition 0.000 claims description 4
- 230000008693 nausea Effects 0.000 claims description 4
- 235000020830 overeating Nutrition 0.000 claims description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical group O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 3
- 210000004916 vomit Anatomy 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims description 2
- 229940081974 saccharin Drugs 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 abstract description 8
- 230000002335 preservative effect Effects 0.000 abstract description 8
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 abstract 1
- 229940083037 simethicone Drugs 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 description 18
- 244000005700 microbiome Species 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 15
- 235000019634 flavors Nutrition 0.000 description 15
- 238000002156 mixing Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 210000004211 gastric acid Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 240000008790 Musa x paradisiaca Species 0.000 description 7
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000001156 gastric mucosa Anatomy 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 235000010419 agar Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000011241 protective layer Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229940069428 antacid Drugs 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- 235000011132 calcium sulphate Nutrition 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 244000303769 Amaranthus cruentus Species 0.000 description 2
- 241000193752 Bacillus circulans Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960004872 nizatidine Drugs 0.000 description 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001331781 Aspergillus brasiliensis Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940101006 anhydrous sodium sulfite Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- HEMWUBDOXTTXSX-UHFFFAOYSA-N butyl 4-hydroxybenzoate;sodium Chemical compound [Na].CCCCOC(=O)C1=CC=C(O)C=C1 HEMWUBDOXTTXSX-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- KRCMKUNIILUXPF-UHFFFAOYSA-N methyl 4-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=C(O)C=C1 KRCMKUNIILUXPF-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- WXSLOYPZKHFWII-UHFFFAOYSA-N propyl 4-hydroxybenzoate;sodium Chemical compound [Na].CCCOC(=O)C1=CC=C(O)C=C1 WXSLOYPZKHFWII-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本發明係關於一種醫藥組合物,其包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽。本發明醫藥組合物在防腐功效方面極佳,且因此可有效地用作該醫藥組合物。
Description
本發明係關於一種醫藥組合物,其包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽。
胃為一種器官,其精細地分解經歷食道之食物以便容易儲存及消化,且控制食物傳送至十二指腸中以與胰臟酶之分泌協調,藉此有助於食物之有效消化及吸收。在食物進入後,胃分泌強酸,亦即胃酸以便消化食物。彼時,胃黏膜保護層保護胃黏膜不受此類胃酸損傷。
然而,胃黏膜保護層易受由來自各種因子之攻擊引起的損傷。作為代表性侵襲性因子,存在胃酸、酒精、吸菸、類固醇、諸如阿司匹林之非類固醇消炎藥(NSAID)、諸如幽門螺旋桿菌(Helicobacter pylori)等之細菌、刺激性食物、營養缺乏、壓力等。當胃黏膜層由此類因素所致而受損時,存在伴有侵蝕、發紅、出血或水腫之炎症之出現。在嚴重情況下,若損傷發展以在胃黏膜中形成孔且甚至損傷黏膜之底部及肌肉層,則出現胃潰瘍。
為了預防及治療如上之胃損傷,有可能使用中和、吸收或抑制胃酸或經施加至胃黏膜以形成保護層之藥物。在市場中出售將磷酸鋁凝膠、鋁鎂加、褐藻酸等用作主要組分之產品。然而,根據患者之口味之多樣化,對在維持胃保護作用的同時,具有較溫和及較新鮮的攝入感覺之產品存在需求。
[
先前技術參考文獻
]
[
專利文獻
]
(專利文獻1)韓國專利註冊號第10-0903743號
本發明之一目的係為了提供一種具有極佳防腐功效之醫藥組合物,其包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽。
此外,本發明之目的係為了提供一種具有極佳防腐功效之用於預防或治療胃腸道失調的醫藥組合物,其包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽,以及一種用於製備其之方法。
本發明之另一目的係為了提供一種用於預防或治療胃腸道失調之方法,其包括向個體投與包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽之醫藥組合物之步驟。
此外,本發明之另一目的係為了提供一種包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽之組合物的用途,其用於預防或治療胃腸道失調。
此外,本發明之另一目的係為了提供一種包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽之組合物的用途,其用於製備用於預防或治療胃腸道失調之藥物。
為達成以上目的,本發明人已繼續研究且因此鑑別出包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷及DL-肉鹼鹽酸鹽之醫藥組合物的抗菌程度可藉由包含洛赫西定鹽來提高,藉此完成本發明。
本發明提供包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽之醫藥組合物。
本發明醫藥組合物顯示改善胃腸道失調之極佳活性,且達成組合物之極佳防腐功效、患者之良好喜愛度及藥療之新鮮感覺。
本發明醫藥組合物甚至在高pH下維持抗菌品質,使得極大抑制微生物之增殖。特定言之,即使在微生物滲入後,本發明之組合物亦可以較快速度殺滅此類微生物,使得組合物可穩定地保存長時間段不受微生物損害。舉例而言,本發明之組合物可顯示出長時間段抗金黃色葡萄球菌
(S. aureus
)、綠膿桿菌
(P. aeruginosa
)、大腸桿菌
(E. coli
)、白色念珠菌
(C. albicans
)、巴西麯黴
(A . brasiliensis
)、環狀芽孢桿菌
(Bacillus circulans
)及其類似物之極佳抗菌活性。
此外,本發明醫藥組合物可維持其中存在之微生物之低含量,即使此類組合物在製備製程期間曝露於外部持續較長時間段。結果,可能不需要對旨在在製備製程期間防止微生物滲入之管理作出巨大投資,使得組合物有利於大量生產及工業用途且在經濟上有效益。
此外,本發明醫藥組合物可長時間維持防腐功效,無論使用何種類型之外部容器以容納組合物,且亦不會造成經吸收至容器之外壁上的問題。
在本發明中,該組合物可包含相對於組合物之總重量5 w/w%至30 w/w%之磷酸鋁凝膠;0.5 w/w%至10 w/w%之氫氧化鎂;0.001 w/w%至1 w/w%之聚二甲矽氧烷;0.1 w/w%至1.5 w/w%之DL-肉鹼鹽酸鹽;及0.001 w/w%至0.05 w/w%之洛赫西定鹽。特定言之,本發明之組合物可包含相對於組合物之總重量10 w/w%至15 w/w%之磷酸鋁凝膠;1 w/w%至5 w/w%之氫氧化鎂;0.01 w/w%至0.5 w/w%之聚二甲矽氧烷;0.4 w/w%至1 w/w%之DL-肉鹼鹽酸鹽;及0.001 w/w%至0.03 w/w%之洛赫西定鹽。
在本發明中,磷酸鋁凝膠之含量可為相對於組合物之總重量5 w/w%至30 w/w%、較佳10 w/w%至15 w/w%。本發明之磷酸鋁凝膠可為滿足美國藥典之需求的一者。本發明之磷酸鋁凝膠在經由該含量範圍內之胃酸之脫酸及中和顯示胃黏膜保護作用的同時,可產生新鮮的攝入感覺。此外,該磷酸鋁凝膠在預防可由氫氧化鎂引起之腹瀉方面起作用。
在本發明中,氫氧化鎂之含量相對於組合物之總重量可為0.5 w/w%至10 w/w%、較佳1 w/w%至5 w/w%。該氫氧化鎂可充當制酸劑且在中和胃腸道內之胃酸方面起作用。此外,該磷酸鋁凝膠在預防可由磷酸鋁凝膠引起之便秘方面起作用。
本發明醫藥組合物顯示中和胃腸道中之胃酸且藉助於磷酸鋁凝膠及氫氧化鎂維持胃中之高pH的緩衝作用,且不引起二級酸反彈。此外,本發明醫藥組合物以使得鋁鹽及鎂鹽以互補方式起作用之方式減少胃腸副作用的出現。
除磷酸鋁凝膠及氫氧化鎂之外,本發明醫藥組合物可進一步包含制酸劑。該額外制酸劑可為例如鋁鹽、鎂鹽、鈣鹽及鈉鹽,尤其氫氧化鋁、矽酸鋁、碳酸鎂、氧化鎂、碳酸鈣及碳酸氫鈉,但不限於此。
本發明醫藥組合物可進一步包含胃酸抑制劑。該胃酸抑制劑可為例如H2
受體拮抗劑及質子泵抑制劑,尤其組織胺拮抗劑(cimetidine)、雷尼替丁(ranitidine)、法莫替丁(famotidine)、尼紮替丁(nizatidine)、奧美拉唑(omeprazole)、埃索美拉唑(esomeprazole)、蘭索拉唑(lansoprazole)、泮托拉唑(pantoprazole)及拉貝拉唑(rabeprazole),但不限於此。
在本發明中,聚二甲矽氧烷之含量相對於組合物之總重量可為0.001 w/w%至1 w/w%、較佳0.01 w/w%至0.5 w/w%。該聚二甲矽氧烷藉由自胃移除氣體來消除腹脹及不適感。
在本發明中,DL-肉鹼鹽酸鹽之含量相對於組合物之總重量可為0.1 w/w%至1.5 w/w%、較佳0.4 w/w%至1.0 w/w%。該DL-肉鹼鹽酸鹽可刺激胃液之分泌且促進胃腸道蠕動。
在本發明中,洛赫西定鹽可選自乙酸洛赫西定、葡糖酸洛赫西定、鹽酸洛赫西定或其組合,且較佳地可為乙酸洛赫西定(二乙酸洛赫西定),但不限於此。在本發明中,洛赫西定鹽之含量相對於組合物之總重量可為0.001 w/w%至0.05 w/w%、較佳0.001 w/w%至0.03 w/w%。該洛赫西定鹽可充當防腐劑。本發明醫藥組合物可藉由包含該洛赫西定鹽來顯示抗各種環境細菌之抗菌作用,使得本發明醫藥組合物在防腐功效方面極佳。本發明醫藥組合物甚至在洛赫西定鹽之低濃度下在防腐功效方面亦極佳。此外,本發明醫藥組合物可藉由包含該洛赫西定鹽來在高pH下,例如甚至在pH 7至9下之維持極佳的抗菌活性。此外,即使在微生物滲入後,本發明醫藥組合物可以較快速度殺滅此類微生物,使得組合物可穩定地保存長時間段不受微生物損害。此外,本發明醫藥組合物可維持其中存在之微生物之低含量,即使此類組合物在製備製程期間曝露於外部持續較長時間段。結果,可能不需要對旨在在製備製程期間防止微生物滲入之管理作出巨大投資,使得組合物有利於大量生產及工業用途且在經濟上有效益。
除洛赫西定鹽以外,本發明醫藥組合物可進一步包含防腐劑。該額外防腐劑可為例如胺基苯甲酸、水合羊毛蠟、無水亞硫酸鈉、去水乙酸鈉、二丁基羥基甲苯、二氯苯甲醇、苯甲酸、苯甲酸鈉、苯甲醇、丁基羥基苯甲醚、丁基羥基甲苯、山梨酸鉀、山梨酸、對羥基苯甲酸甲酯、對羥基苯甲酸甲酯鈉、對羥基苯甲酸乙酯、對羥基苯甲酸丙酯、對羥基苯甲酸丙酯鈉、對羥基苯甲酸丁酯鈉及苯氧基乙醇,但不限於此。
本發明醫藥組合物可進一步包含黏度控制劑。該黏度控制劑可為例如瓊脂、果膠、硫酸鈣、三仙膠、聚乙烯吡咯啶酮、乙基纖維素、羧甲基纖維素鈉、中國魚膠、褐藻酸、褐藻酸鹽、單硬脂酸鋁、膨潤土、卡波姆、卡波姆共聚物、角叉菜膠、糊精、明膠、瓜爾膠及二氧化矽,但不限於此,且可較佳選自瓊脂、果膠、硫酸鈣、三仙膠或其組合。在本發明之一較佳實施例中,本發明醫藥組合物包含瓊脂、果膠、硫酸鈣及三仙膠。該等瓊脂及果膠可藉由與磷酸鋁凝膠相互作用來增強覆蓋胃黏膜之作用。該三仙膠可有效控制醫藥組合物之黏度。在本發明中,三仙膠相對於組合物之總重量之含量可為0.1 w/w%至1 w/w%、較佳0.1 w/w%至0.7 w/w%。本發明醫藥組合物具有如此適當的黏度,使得口腔中之殘餘物的量在其攝入後減少,且如此容易地經由咽喉吞咽,使得可增強患者對藥療之順應性。
本發明醫藥組合物可進一步包含甜味劑。該甜味劑可選自例如蔗糖素、白糖、酶改質之甜菊、木糖醇、糖精、糖精鹽、甜菊苷、山梨糖醇、右旋糖、甘草素或其組合,但不限於此,且可較佳選自蔗糖素、白糖、酶改質之甜菊糖或其組合。該甜味劑之量可由熟習此項技術者適當地選擇。在本發明之一較佳實施例中,本發明醫藥組合物包含白糖及蔗糖素作為甜味劑。與其他甜味劑相比,白糖具有如此極其純淨的口味,使得其可促成本發明醫藥組合物具有新鮮的攝入感覺。在本發明中,白糖相對於醫藥組合物之總重量之含量可為5 w/w%至20 w/w%、較佳5 w/w%至15 w/w%。在本發明之一較佳例示性實施例中,蔗糖素具有覆蓋洛赫西定之不合意的苦味之如此極佳作用,使得可增強本發明醫藥組合物之攝入感覺。該蔗糖素相對於醫藥組合物之總重量之含量可為0.001 w/w%至0.1 w/w%、較佳0.005 w/w%至0.03 w/w%。
本發明醫藥組合物可進一步包含調味劑。該調味劑可為例如合成香料油、天然油、植物萃取物及其類似物,尤其香蕉香料、蘋果香料、橙香料、香蕉混合物香料、葡萄柚香料、混合漿果香味、萊姆橙香料、薰衣草香料、檸檬香料、薄荷香料、胡椒薄荷香料及草莓香料,但不限於此。該調味劑之量可由熟習此項技術者適當地選擇。在本發明之一較佳實施實施例中,本發明醫藥組合物包含香蕉混合物香料作為調味劑。特定言之,該香蕉混合物香料可為香蕉香料與草莓香料之組合,且可為例如商業上分銷之香蕉混合物香料B-17026。
特定言之,本發明醫藥組合物之劑型可為經口液體組合物、較佳懸浮液。該懸浮液可包含水、較佳純化水作為賦形劑。該懸浮液之黏度在20℃下可為200 cps至2200 cps、較佳700 cps至1900 cps且更佳900 cps至1800 cps。患者之偏好可視對醫藥組合物之黏度的控制而變化。本發明醫藥組合物顯示如此適當的黏度,使得口腔中之殘餘物的量在其攝入後減少,且易於經由咽喉吞咽。因此,本發明醫藥組合物可增強患者對藥療之順應性且改善對藥療之堅持性。
每本發明醫藥組合物之每單位劑型磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽之量可由熟習此項技術者確定。
每本發明醫藥組合物之單位劑型磷酸鋁凝膠之量可較佳為每100 g醫藥組合物之單位劑型5 g至30 g、更佳10 g至15 g且最佳約12.5 g;氫氧化鎂之量可為每100 g醫藥組合物之單位劑型0.5 g至10 g、更佳1 g至5 g且最佳約2 g;聚二甲矽氧烷之量可為每100 g醫藥組合物之單位劑型0.001 g至1 g、更佳0.01 g至0.5 g且最佳約0.225 g;DL-肉鹼鹽酸鹽之量可為每100 g醫藥組合物之單位劑型0.1 g至1.5 g、更佳0.4 g至1.0 g且最佳約0.75 g;且洛赫西定鹽之量可為每100 g醫藥組合物之單位劑型0.001 g至0.05 g、較佳0.001 g至0.03 g且最佳約0.015 g。
本發明醫藥組合物包含每單位劑型該範圍之磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽,藉此顯示極佳的脫酸作用、脫氣作用及胃腸促動力作用,且亦顯示顯著高的抗菌活性,且因此顯示顯著極佳的防腐功效。
本發明醫藥組合物可進一步包含在不逐漸損害本發明之作用的範圍內之醫藥學上可接受之添加劑。該添加劑可為例如溶解助劑、穩定劑、懸浮劑、界面活性劑、抗氧化劑及pH調節劑,但不限於此。
本發明醫藥組合物可用於預防及治療胃腸道失調。特定言之,本發明醫藥組合物可藉由吸收及中和腸道氣體、細菌、毒素、病毒或其類似物來預防及治療胃腸道失調。特定言之,本發明醫藥組合物亦可用於藉由中和胃酸來預防及治療胃酸過多、胃灼熱、嗝出一點酸嘔吐物、胃不適或飲食過量。特定言之,本發明醫藥組合物亦可藉由自胃腸道移除氣體來緩解胃脹感或胃不適感。特定言之,本發明醫藥組合物亦刺激胃液之分泌且促進胃腸道蠕動,使得組合物可增強胃之消化能力且可用於預防及治療食慾不振及厭食症。特定言之,本發明醫藥組合物亦施用於胃黏膜上、沈積於其上且在潰瘍表面上形成保護層,使得組合物可用於預防及治療噁心、嘔吐或胃疼痛。
因此,本發明醫藥組合物可意欲用於預防或治療選自例如以下之胃腸道失調:胃酸過多、胃灼熱、胃不適感、胃脹感、胃不適、噁心、嘔吐、胃疼痛、嗝出一點酸嘔吐物、食慾不振、厭食症、消化不良、飲食過量或其組合。
本發明醫藥組合物可藉由包含該洛赫西定鹽來顯著減少環境細菌之含量。因此,本發明醫藥組合物在防腐功效方面極佳。
本發明醫藥組合物具有良好口味及適當黏度。因此,本發明醫藥組合物可藉助於輕度及新鮮的攝入感覺增強患者之喜愛度且提高患者對藥療之順應性及堅持性。
本發明提供一種用於製備用於預防或治療胃腸道失調之醫藥組合物之方法,該醫藥組合物包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽。
用於製備根據本發明醫藥組合物之方法可包括:將氫氧化鎂及聚二甲矽氧烷與純化水混合之第一混合步驟;加熱獲自該第一混合步驟之所得混合溶液,藉此溶解該混合溶液之步驟;將磷酸鋁凝膠添加至該溶液中,藉此混合該溶液之第二混合步驟;冷卻該混合物之步驟;將該經冷卻之混合物與洛赫西定鹽混合之第三混合步驟;及冷卻獲自該第三混合步驟之混合物之步驟;及將該經冷卻之混合物與DL-肉鹼鹽酸鹽混合之第四混合步驟。
本發明提供一種預防或治療胃腸道失調之方法,其包括向有需要之個體投與包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽之醫藥組合物的步驟。
該胃腸道失調意謂諸如胃酸過多、胃灼熱、胃不適感、胃脹感、胃不適、噁心、嘔吐、胃疼痛、嗝出一點酸嘔吐物、食慾不振、厭食症、消化不良、飲食過量等症狀。
該預防意謂減少胃腸道失調或由胃腸道失調引起之症狀之病理性出現者。該治療意謂改善胃腸道失調之至少一個症狀或停止其進展者,且可涵蓋習知使用之治療的含義。
該投藥可為經口投與。在向個體投與該醫藥組合物之情況下,此類組合物可以預防或治療胃腸道失調所必需的有效量投與。
本發明提供一種包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽之組合物的用途,其用於預防或治療胃腸道失調。
本發明提供一種包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽之組合物的用途,其用於製備用於預防或治療胃腸道失調之藥物。用於製備根據本發明之藥物的組合物可與可接受之載劑混合等,且進一步包含其他藥劑。
若不彼此矛盾,則本發明之組合物、治療方法及用途中提及之物質同樣適用。
有利作用
本發明醫藥組合物甚至在高pH下維持抗菌品質,使得極大抑制微生物之增殖。即使在微生物滲入後,組合物亦可以較快速度殺滅此類微生物,使得組合物可穩定地保存長時間段不受微生物損害。因此,本發明醫藥組合物在防腐功效方面顯著極佳。
此外,本發明醫藥組合物可長時間維持防腐功效,無論使用何種類型之外部容器以容納組合物,且亦不會造成經吸收至容器之外壁上的問題。
此外,本發明醫藥組合物可維持其中存在之微生物之低含量,即使此類組合物在製備製程期間曝露於外部持續較長時間段。結果,可能不需要對旨在在製備製程期間防止微生物滲入之管理作出巨大投資,使得組合物有利於大量生產及工業用途且在經濟上有效益。
此外,本發明醫藥組合物具有不太苦的味道,亦具有如此適當的黏度,使得口腔中之殘餘物的量在其攝入後減少,且如此容易地經由咽喉吞咽,使得達成患者之高喜愛度且顯著增強對藥療之順應性及對藥療之堅持性。
此外,本發明醫藥組合物顯示改善胃腸道失調之極佳活性。
因此,本發明醫藥組合物可有效用作醫藥組合物,因為其在防腐功效方面極佳;其製備製程有利於大量生產且經濟上有效益;增強對藥物之順應性及對藥物之堅持性;且改善胃腸道失調之活性亦極佳。
本發明之最佳模式
在下文中,將經由具體例示性實施例較詳細地描述本發明。然而,僅出於說明本發明之目的提供以下例示性實施例,且因此本發明不限於此。
實例 1
將氫氧化鎂、聚二甲矽氧烷、瓊脂、果膠、三仙膠、硫酸鈣及白糖在25℃下以如下表1中所指示之此量混合於純化水中。將所得混合溶液加熱直至70℃,使得混合物溶解10分鐘至20分鐘。添加磷酸鋁凝膠且以如表1中所指示之此量將其混合至其中,且將混合物冷卻至50℃至60℃。添加乙酸洛赫西定且以如表1中所指示之此量混合於該經冷卻之混合物中。將乙酸洛赫西定(二乙酸洛赫西定)混合於其中,且冷卻至30℃或更低,其後以如下表1中所指示之此量向其中添加DL-肉鹼鹽酸鹽,且進一步添加適合量之蔗糖素(0.005 g至0.03 g)、混合且在室溫下冷卻。最後,以如表1中所指示之此量向其中添加香蕉混合物香料,其後將所得混合物混合、研磨且充裝以製備總計100 g之懸浮液。
[表1]
實例 2 及實例 3
藉助於與實例1中所示相同之方法製備懸浮液,例外為所用乙酸洛赫西定之含量分別為0.02 g及0.03 g。
實驗實例 1 . 鑑別防腐功效
藉助於Korean Pharmacopoeia之一般測試方法之「防腐功效測試方法」鑑別根據實例1至3之組合物的防腐功效。為了確認防腐功效為足夠的,當用細菌接種時,細菌之數目應在接種之後14天中自經接種細菌之彼數目降低至10%或更低,且亦在之後28天中,細菌之數目應維持或減小至等於或低於在以上之後14天中所量測的細菌之彼含量的含量。且在真菌之情況下,已確認,若真菌之數目等於或低於在用真菌接種之後14天中經接種真菌之彼數目,且亦若真菌之數目等於或低於在之後28中經接種真菌之彼數目,則表現防腐功效。換言之,根據下式量測減少率(%),亦即,(經接種細菌之數目-活細菌之數目)/經接種細菌之數目 × 100。若減少率為90%或更高,則判定存在防腐劑之防腐功效。若在所有測試細菌中均存在防腐功效,則判定防腐功效為適合的。
作為測試菌株,使用以下:標準細菌,亦即,金黃色葡萄球菌
、綠膿桿菌
及大腸桿菌
;標準真菌,亦即,白色念珠菌
及巴西麯黴
(Aspergillus brasiliensis
);及環境細菌,亦即,環狀芽孢桿菌
。在胰蛋白酶大豆瓊脂培養基中培養細菌,且在薩蒲洛氏右旋糖瓊脂(Sabouraud Dextrose Agar)培養基中培養真菌。
作為對防腐功效之該測試之結果,根據本發明之實例1的組合物不僅滿足關於所有該等菌株的防腐功效之準則,且亦顯示減少率為99%或更高之顯著極佳的抗菌活性。
Claims (14)
- 一種醫藥組合物,其包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及洛赫西定鹽(chlorhexidine salt),其中該洛赫西定鹽為乙酸洛赫西定。
- 如請求項1之醫藥組合物,其進一步包含甜味劑。
- 如請求項2之醫藥組合物,其中該甜味劑選自酶改質之甜菊、木糖醇、糖精、糖精鹽、甜菊苷、山梨糖醇、右旋糖、甘草素、白糖、蔗糖素或其組合。
- 如請求項2之醫藥組合物,其中該甜味劑為白糖及蔗糖素。
- 如請求項4之醫藥組合物,其中白糖相對於該醫藥組合物之總重量之含量為5w/w%至20w/w%,且蔗糖素相對於該醫藥組合物之總重量之含量為0.001w/w%至0.1w/w%。
- 如請求項1之醫藥組合物,其中選自瓊脂、果膠、硫酸鈣、三仙膠或其組合之黏度控制劑進一步包含於其中。
- 如請求項1之醫藥組合物,其進一步包含調味劑。
- 如請求項1之醫藥組合物,其中劑型為懸浮液。
- 如請求項8之醫藥組合物,其中該懸浮液之黏度在20℃下為700cps至1500cps。
- 如請求項1之醫藥組合物,其中該組合物包含相對於該組合物之總重量10w/w%至15w/w%之磷酸鋁凝膠;1w/w%至5w/w%之氫氧化鎂;0.01w/w%至0.5w/w%之聚二甲矽氧烷;0.4w/w%至1.0w/w%之DL-肉鹼鹽酸鹽;及0.001w/w%至0.03w/w%之洛赫西定鹽。
- 如請求項10之醫藥組合物,其中該洛赫西定鹽為乙酸洛赫西定。
- 如請求項1之醫藥組合物,其中該組合物意欲用於預防或治療選自以下之胃腸道失調:胃酸過多、胃灼熱、胃不適感、胃脹感、胃不適、噁心、嘔吐、胃疼痛、隔出一點酸嘔吐物、食慾不振、厭食症、消化不良、飲食過量或其組合。
- 如請求項1之醫藥組合物,其中該組合物意欲用於經口組合物。
- 一種醫藥組合物之用途,其用於製造用於預防或治療胃腸道失調之藥劑,其中該醫藥組合物包含磷酸鋁凝膠、氫氧化鎂、聚二甲矽氧烷、DL-肉鹼鹽酸鹽及乙酸洛赫西定。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180043360A KR101926853B1 (ko) | 2018-04-13 | 2018-04-13 | 약학적 조성물 |
| KR10-2018-0043360 | 2018-04-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201946612A TW201946612A (zh) | 2019-12-16 |
| TWI698258B true TWI698258B (zh) | 2020-07-11 |
Family
ID=64669671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108112937A TWI698258B (zh) | 2018-04-13 | 2019-04-12 | 醫藥組合物 |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR101926853B1 (zh) |
| CN (1) | CN111836629A (zh) |
| TW (1) | TWI698258B (zh) |
| WO (1) | WO2019199100A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101926853B1 (ko) * | 2018-04-13 | 2018-12-07 | 보령제약 주식회사 | 약학적 조성물 |
| US11396139B2 (en) | 2019-05-22 | 2022-07-26 | The Regents Of The University Of Michigan | High-speed polymer-to-metal direct joining system and method |
| US12318861B2 (en) | 2020-01-02 | 2025-06-03 | The Regents Of The University Of Michigan | Methods of joining dissimilar metals without detrimental intermetallic compounds |
| US11890788B2 (en) | 2020-05-20 | 2024-02-06 | The Regents Of The University Of Michigan | Methods and process for producing polymer-metal hybrid components bonded by C—O-M bonds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0130427B1 (ko) * | 1994-08-01 | 1998-04-09 | 김승호 | 복합 제산제 조성물 |
| JPH08259445A (ja) * | 1995-01-27 | 1996-10-08 | Takeda Chem Ind Ltd | 胃排出能改善性医薬組成物 |
| KR0174648B1 (ko) * | 1996-11-04 | 1999-10-01 | 김승호 | 위기능 조절제를 함유하는 복합 제산제 조성물 |
| US5914135A (en) * | 1997-04-16 | 1999-06-22 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
| BRPI0821871A2 (pt) * | 2008-01-03 | 2015-06-16 | Wockhardt Research Center | Suspensão farmacêutica oral compreendendo paracetamol e ibuprofeno |
| KR101926853B1 (ko) * | 2018-04-13 | 2018-12-07 | 보령제약 주식회사 | 약학적 조성물 |
-
2018
- 2018-04-13 KR KR1020180043360A patent/KR101926853B1/ko active Active
-
2019
- 2019-04-12 CN CN201980018249.6A patent/CN111836629A/zh active Pending
- 2019-04-12 WO PCT/KR2019/004415 patent/WO2019199100A1/ko not_active Ceased
- 2019-04-12 TW TW108112937A patent/TWI698258B/zh active
Non-Patent Citations (5)
| Title |
|---|
| Med.J.Cairo Univ.,Vol.77,no.4,June 2009,p.43-51 |
| Med.J.Cairo Univ.,Vol.77,no.4,June 2009,p.43-51 Turk.J.Med.Sci.,15.06.2015,p.903-909 * |
| Turk.J.Med.Sci.,15.06.2015,p.903-909。 |
| 金吉胃福適凝膠,gelfos M,衛署藥書字第024246號 * |
| 金吉胃福適凝膠,gelfos M,衛署藥書字第024246號。 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101926853B1 (ko) | 2018-12-07 |
| TW201946612A (zh) | 2019-12-16 |
| CN111836629A (zh) | 2020-10-27 |
| WO2019199100A1 (ko) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI698258B (zh) | 醫藥組合物 | |
| US7776831B2 (en) | Use of antifungal compositions to treat upper gastrointestinal conditions | |
| US20240189228A1 (en) | Suckable and/or melt-in-mouth tablet based on hyaluronic acid and chondroitin sulphate and salts thereof | |
| US20080160087A1 (en) | Gel preparation for oral administration | |
| US20070202058A1 (en) | Compositions for treating gastric reflux | |
| EP3703657B1 (en) | Suckable and/or melt-in-mouth tablet based on hyaluronic acid and chondroitin sulphate and salts thereof for use in the treatment of a subpopulation of gerd patients | |
| JP2024525096A (ja) | アルギネート、ポリリジン、及び種子防腐剤を使用する胃酸を中和するための方法 | |
| JP6117591B2 (ja) | モサプリドと制酸剤とを含有する医薬組成物 | |
| US20070203242A1 (en) | Method for treating gastric reflux | |
| JPWO2014010658A1 (ja) | ヒハツ配合製剤 | |
| US20110287062A1 (en) | Chewable Formulation Comprising Alginate, Bicarbonate And Carbonate | |
| CN1867325A (zh) | 含双胍系药剂的胶状制剂 | |
| US20180140630A1 (en) | Combination of an h2-receptor antagonist, antacid, and alginic acid to treat episodic heartburn | |
| KR20140093461A (ko) | 음용감이 우수한 소화기능 개선용 민트명수액 및 그 제조 방법 | |
| US11723939B2 (en) | Composition for gastric and oesophageal diseases | |
| JP2002509539A (ja) | 制酸剤とパパインの組合せ物 | |
| RS66522B1 (sr) | Kombinacija za upotrebu u lečenju ekstra-ezofagealnih simptoma gastričnog refluksa | |
| KR20110075337A (ko) | 위장 질환 치료용 조성물 및 이의 제조 방법 | |
| JP7634160B2 (ja) | 固形製剤 | |
| WO2010108494A1 (en) | Dayspepsia treatment with alginate | |
| ES2274550T3 (es) | Procedimientos y composiciones para prevenir y tratar ardor de estomago. | |
| HK40032166B (zh) | 用於治疗gerd患者亚群的基於透明质酸和硫酸软骨素及其盐的可吸吮和/或口内融化的片剂 | |
| US20060094760A1 (en) | Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution | |
| KR20040026843A (ko) | 니코틴을 함유한 하드츄잉캔디 및 그의 제조방법 | |
| Tighici et al. | The treatment of gastroduodenal ulcer in children. |

